Abbisko Therapeutics Receives CDE Approval of Breakthrough Therapy Designation for Irpagratinib (ABSK011) in the Treatment of HCC ...Middle East

SHANGHAI, May 26, 2025 /PRNewswire/ -- Abbisko Therapeutics (HKEX Code: 02256) announced that its self-developed, highly selective small molecule FGFR4 inhibitor, irpagratinib (ABSK011), has received approval of Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of...

Read More Details
Finally We wish PressBee provided you with enough information of ( Abbisko Therapeutics Receives CDE Approval of Breakthrough Therapy Designation for Irpagratinib (ABSK011) in the Treatment of HCC )

Also on site :

• Russia reliable partner to Africa in strengthening sovereignty – Lavrov
• Ship carrying oil and hazardous cargo sinks off Kerala coast
• Trysull and Seisdon WI enjoy art workshop